PFE250502C20500
- 3.51
- +0.99+39.29%
Pfizer Newsroom
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Pfizer First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Pfizer Positioned for Growth: Buy Rating Affirmed Due to Operational Efficiency, Strategic Capital Allocation, and Undervaluation
Citigroup Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating
Goldman Sachs Ups Price Target on Pfizer to $27 From $25, Maintains Neutral Rating
Market Rally at Risk as Tariffs Damage Spreads. -2-
Morgan Stanley Lifts Price Target on Pfizer to $32 From $31, Keeps Equalweight Rating
Express News | Pfizer : Leerink Partners Cuts Target Price to $26 From $28
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Pfizer's Mixed Q1 Results and Uncertain Long-Term Prospects Justify Hold Rating
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone
Asthma and HIV drugs drive performance growth. GlaxoSmithKline (GSK.US) Q1 profits exceeded expectations, maintaining the annual performance outlook.
The company's profits in the first quarter exceeded expectations, particularly strong sales of asthma and HIV treatment drugs offset the negative impact of the overall vaccine Business line sales performance being below expectations.
Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance
Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Pfizer's Earnings Call: Growth Amidst Challenges
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $24
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
On April 29th, the top 20 US stock transaction amounts: Amazon reveals tariff costs and faces anger from the White House.
On Tuesday, Tesla ranked first in US stock trading volume, rising by 2.15% with a transaction of 30.765 billion US dollars. As such, Tesla's stock price has increased for six consecutive trading days, with a total rise of over 28%. US Energy storage project manufacturers and developers stated that this Industry will invest 100 billion US dollars in this decade to establish a fully localized Battery supply chain. The US Clean Energy Association noted that this 100 billion US dollars investment will create 0.35 million jobs, including 10 billion to 15 billion US dollars in ongoing projects. Projects include Tesla's Battery factory located in Sparks, Nevada. According to media reports on Tuesday,